Core Viewpoint - Inspire Medical Systems, Inc. is facing allegations of misleading investors regarding the launch of its new product, Inspire V, which reportedly failed due to poor demand and inadequate preparations [1]. Group 1: Allegations and Issues - The complaint alleges that the launch of Inspire V was a disaster, with significant surplus inventory at treatment centers and reluctance from providers to adopt the new treatment [1]. - Defendants are accused of making false statements about the successful launch, while failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [1]. - Critical issues included the lack of updates to insurer claims software and the absence of Medicare reimbursement at the time of launch, which were fundamental for the product's success [1]. Group 2: Class Action Details - Shareholders who purchased shares of INSP between August 6, 2024, and August 4, 2025, are encouraged to register for the class action, with a deadline for lead plaintiff appointment set for January 5, 2026 [2]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case's progress, with no cost or obligation to join [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that inflated stock prices [3].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the launch and demand for its Inspire V device, leading to significant financial losses for investors [3][5]. Group 1: Allegations and Legal Action - The complaint against Inspire Medical Systems claims that the company and its executives violated federal securities laws by making false or misleading statements about the market demand for the Inspire V device and the steps taken for its launch [3]. - Investors are reminded of the January 5, 2026 deadline to seek the role of lead plaintiff in the class action lawsuit [1][6]. Group 2: Launch Issues and Financial Impact - On August 4, 2025, Inspire Medical announced delays in the launch of the Inspire V device due to incomplete training and onboarding at treatment centers, as well as billing and reimbursement challenges [4]. - The company reported weak demand and excess inventory for the Inspire V, leading to a more than 80% cut in its 2025 earnings guidance [5]. - Following these announcements, Inspire's stock price plummeted over 32% in one day, from $129.95 to $87.91, resulting in a loss of approximately $1.2 billion in market capitalization [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on January 5, 2026, for a class action lawsuit related to alleged misrepresentations about the company's sleep apnea device, Inspire V [1][5]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can submit a form online or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by January 5, 2026, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements, including the largest securities class action settlement against a Chinese company and being ranked highly for the number of settlements achieved [4]. Group 3: Allegations Against Inspire Medical - The lawsuit claims that Inspire Medical misrepresented key facts about the market demand for its Inspire V device and failed to disclose whether necessary steps for its launch were taken, leading to misleading statements that inflated investor confidence [5]. - When the true details about the product and its market performance became known, investors allegedly suffered damages [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of false and misleading statements regarding the launch of its Inspire V device, which has led to significant financial losses for investors [3][5]. Group 1: Legal Investigation - The law firm is reminding investors of the January 5, 2026 deadline to seek the role of lead plaintiff in a federal securities class action against Inspire Medical [3]. - The firm encourages investors who suffered losses in Inspire Medical to contact them directly to discuss their legal options [1][9]. Group 2: Company Performance and Issues - Inspire Medical announced significant setbacks in the launch of its Inspire V device on August 4, 2025, citing delays in training and onboarding at treatment centers [6]. - The company faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, preventing implanting centers from billing for procedures [6]. - Inspire Medical reported weak demand and excess inventory for the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [7]. Group 3: Market Impact - Following the announcement of these issues, Inspire Medical's stock price plummeted over 32% in one day, from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [7].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., et al., No. 0:25-cv-04247 [3]. - Investors have until January 5, 2026, to request to be appointed to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - The complaint alleges that Inspire misled investors by claiming it was prepared for the launch of Inspire V, while in reality, it failed to adequately prepare clinicians and payors, leading to delays in adoption [5][6]. - On August 4, 2025, Inspire announced that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price fell by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

WHAT'S NEXT? If you suffered a loss in Inspire Medical Systems, Inc. during the relevant time frame, you have until January 5, 2026 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team ...

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - Inspire allegedly misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Inspire Medical Systems, Inc. ("Inspire Medical Systems, Inc." or the "Company") (NYSE: INSP) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Inspire Medical Systems, Inc. investors who were adversely affected by alleged securities fraud between August 6, 2024 and August 4, 2025. Follow the link below to get more information and be contacted by a member of our team ...